Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Damoktokog alfa pegol

Klassificering: B

Preparat: Jivi

ATC kod: B02BD02

Substanser: damoktokog alfa pegol

Sammanfattning

Det saknas publicerade kontrollerade studier om skillnader mellan könen avseende effekt, säkerhet och farmakokinetik för damoktokog alfa pegol.

Additional information

Damoctocog alfa pegol is a pegylated recombinant factor VIII product used in treatment of acute bleeding episodes, perioperative management and routine prophylaxis in previously treated patients with hemophilia A [1]. Hemophilia A (deficiency in coagulation factor VIII) is an inherited X-linked disease and thus affects primarily men although women also can be affected (for example because of skewed inactivation of chromosome X) [2]. The occurrence of hemophilia A in women is very rare and data in women is not available [1].

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of damoctocog alfa pegol have been found.

Effects

No studies with a clinically relevant sex analysis regarding the efficacy of damoctocog alfa pegol have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding the safety of damoctocog alfa pegol have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Nästan enbart män hämtade ut läkemedel innehållande koagulationsfaktor VIII (ATC-kod B02BD02) på recept i Sverige år 2020, totalt 428 män och 3 kvinnor [3].

Uppdaterat: 2021-06-07

Litteratursökningsdatum: 2021-05-25

Referenser

  1. Jivi (damoctocog alfa pegol). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2018-11-22, cited 2021-05-25]
  2. Mehta P and Reddivari AKR. Hemophilia, in StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
  3. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.] länk

Författare: Therese Wennersten, Linnéa Karlsson Lind

Faktagranskat av: Diana Rydberg

Godkänt av: Karin Schenck-Gustafsson